{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T16:42:51Z","timestamp":1793378571690,"version":"4.5.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.lungcan.2025.108856","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:34:18Z","timestamp":1764117258000},"page":"108856","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Real-world use of and clinical outcomes with dacomitinib as first-line therapy in Asian patients with EGFR mutation\u2013positive locally advanced or metastatic non-small cell lung cancer: Final analysis of the ARIA study"],"prefix":"10.1016","volume":"211","author":[{"given":"Lin","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junling","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3474-2809","authenticated-orcid":false,"given":"Chong-Rui","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6101-5500","authenticated-orcid":false,"given":"Bivas","family":"Biswas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0099-1476","authenticated-orcid":false,"given":"Somnath","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke-Jing","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziling","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ullas","family":"Batra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2620-9174","authenticated-orcid":false,"given":"Gwo Fuang","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John Low","family":"Seng Hooi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1671-1408","authenticated-orcid":false,"given":"You","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingfang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4923-4230","authenticated-orcid":false,"given":"Lye Mun","family":"Tho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4404-8768","authenticated-orcid":false,"given":"Shan","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6734-820X","authenticated-orcid":false,"given":"Hui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5161-6775","authenticated-orcid":false,"given":"Chew Hooi","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3611-0258","authenticated-orcid":false,"given":"Yi-Long","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.lungcan.2025.108856_b0005","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.ccm.2011.09.001","article-title":"Lung cancer: epidemiology, etiology, and prevention","volume":"32","author":"Dela Cruz","year":"2011","journal-title":"Clin. Chest Med."},{"issue":"1","key":"10.1016\/j.lungcan.2025.108856_b0010","first-page":"48","article-title":"Epidermal growth factor receptor (EGFR) in lung cancer: an overview and update","volume":"2","author":"Bethune","year":"2010","journal-title":"J. Thorac. Dis."},{"issue":"1","key":"10.1016\/j.lungcan.2025.108856_b0015","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0014-4827(02)00098-8","article-title":"Epidermal growth factor receptor: mechanisms of activation and signalling","volume":"284","author":"Jorissen","year":"2003","journal-title":"Exp. Cell Res."},{"issue":"48","key":"10.1016\/j.lungcan.2025.108856_b0020","doi-asserted-by":"crossref","first-page":"78985","DOI":"10.18632\/oncotarget.12587","article-title":"The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis","volume":"7","author":"Zhang","year":"2016","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.lungcan.2025.108856_b0025","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/JTO.0000000000000033","article-title":"A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER)","volume":"9","author":"Shi","year":"2014","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2025.108856_b0030","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.lungcan.2021.08.001","article-title":"The expanding capability and clinical relevance of molecular diagnostic technology to identify and evaluate EGFR mutations in advanced\/metastatic NSCLC","volume":"160","author":"Shah","year":"2021","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2025.108856_b0035","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdy275","article-title":"Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Planchard","year":"2018","journal-title":"Ann. Oncol."},{"issue":"12","key":"10.1016\/j.lungcan.2025.108856_b0040","doi-asserted-by":"crossref","DOI":"10.3390\/genes13122183","article-title":"Mechanisms of EGFR-TKI-induced apoptosis and strategies targeting apoptosis in EGFR-mutated non-small cell lung cancer","volume":"13","author":"Nishihara","year":"2022","journal-title":"Genes (Basel)"},{"issue":"1","key":"10.1016\/j.lungcan.2025.108856_b0045","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s13045-022-01391-4","article-title":"Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance","volume":"15","author":"Fu","year":"2022","journal-title":"J. Hematol. Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2025.108856_b0050","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1093\/annonc\/mdw611","article-title":"Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial","volume":"28","author":"Paz-Ares","year":"2017","journal-title":"Ann. Oncol."},{"issue":"11","key":"10.1016\/j.lungcan.2025.108856_b0055","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/S1470-2045(17)30608-3","article-title":"Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial","volume":"18","author":"Wu","year":"2017","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2025.108856_b0060","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.lungcan.2025.108856_b0065","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1158\/1535-7163.MCT-07-2232","article-title":"Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor","volume":"7","author":"Gonzales","year":"2008","journal-title":"Mol. Can. Ther."},{"key":"10.1016\/j.lungcan.2025.108856_b0070","first-page":"285","article-title":"Toward precision medicine with next-generation EGFR inhibitors in non-small-cell lung cancer","volume":"7","author":"Yap","year":"2014","journal-title":"Pharmgenomics Pers. Med."},{"key":"10.1016\/j.lungcan.2025.108856_b0075","unstructured":"Pfizer. Vizimpro (dacomitinib) prescribing information 2018 [updated September 2018]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/211288s000lbl.pdf."},{"key":"10.1016\/j.lungcan.2025.108856_b0080","unstructured":"Pfizer. Dacomitinib Tablets Labeling Document (China) 2019 [updated August 2021]."},{"issue":"11","key":"10.1016\/j.lungcan.2025.108856_b0085","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1080\/14656566.2020.1746269","article-title":"Is there a role for dacomitinib, a second-generation irreversible inhibitor of the epidermal-growth factor receptor tyrosine kinase, in advanced non-small cell lung cancer?","volume":"21","author":"Bergonzini","year":"2020","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.lungcan.2025.108856_b0090","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.564234","article-title":"Modelled economic analysis for dacomitinib\u2013a cost effectiveness analysis in treating patients with EGFR-mutation-positive non-small cell lung cancer in China","volume":"11","author":"Yu","year":"2021","journal-title":"Front. Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2025.108856_b0095","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1358\/dot.2019.55.4.2965337","article-title":"Dacomitinib, a second-generation irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) to treat non-small cell lung cancer","volume":"55","author":"Nagano","year":"2019","journal-title":"Drugs Today (Barc)"},{"issue":"8","key":"10.1016\/j.lungcan.2025.108856_b0100","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/j.jtho.2021.02.004","article-title":"Lung cancer in India","volume":"16","author":"Singh","year":"2021","journal-title":"J. Thorac. Oncol."},{"issue":"13","key":"10.1016\/j.lungcan.2025.108856_b0105","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23137037","article-title":"State-of-the-art molecular oncology of lung cancer in Taiwan","volume":"23","author":"Luo","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.lungcan.2025.108856_b0110","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s40801-022-00344-0","article-title":"Treatment patterns, clinical outcomes and health care resource utilisation in patients with EGFR-mutated metastatic non-small cell lung cancer: a real-world study in South Korea","volume":"10","author":"Molife","year":"2023","journal-title":"Drugs Real World Outcomes."},{"issue":"22","key":"10.1016\/j.lungcan.2025.108856_b0115","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1200\/JCO.2018.78.7994","article-title":"Improvement in overall survival in a randomized study that compared dacomitinib with gefitinib in patients with advanced non-small-cell lung cancer and EGFR-activating mutations","volume":"36","author":"Mok","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2025.108856_b0120","first-page":"176","article-title":"Safety and efficacy of first-line dacomitinib in Asian patients with EGFR mutation-positive non-small cell lung cancer: results from a randomized, open-label, phase 3 trial (ARCHER 1050)","volume":"154","author":"Cheng","year":"2021","journal-title":"Lung Can."},{"issue":"3","key":"10.1016\/j.lungcan.2025.108856_b0125","article-title":"Clinical predictors of response to EGFR-tyrosine kinase inhibitors in EGFR-mutated non-small cell lung cancer: a real-world multicentric cohort analysis from India","volume":"44","author":"Garg","year":"2020","journal-title":"Curr. Probl. Can."},{"issue":"7","key":"10.1016\/j.lungcan.2025.108856_b0130","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1111\/1759-7714.13090","article-title":"Real-world data on EGFR\/ALK gene status and first-line targeted therapy rate in newly diagnosed advanced non-small cell lung cancer patients in Northern China: a prospective observational study","volume":"10","author":"Liang","year":"2019","journal-title":"Thorac Can."},{"issue":"1","key":"10.1016\/j.lungcan.2025.108856_b0135","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1186\/s12885-019-6107-1","article-title":"Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study","volume":"19","author":"Ho","year":"2019","journal-title":"BMC Can."},{"issue":"10","key":"10.1016\/j.lungcan.2025.108856_b0140","doi-asserted-by":"crossref","first-page":"S1106","DOI":"10.1016\/j.jtho.2021.08.513","article-title":"P48.02 Real-world data of dacomitinib in EGFR TKI-naive patients with advanced epidermal growth factor receptor-positive non-small cell lung cancer","volume":"16","author":"Zhang","year":"2021","journal-title":"J. Thorac. Oncol."},{"issue":"13","key":"10.1016\/j.lungcan.2025.108856_b0145","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.2217\/fon-2018-0944","article-title":"Management of common adverse events related to first-line dacomitinib use in EGFR mutation-positive non-small-cell lung cancer: a pooled safety analysis","volume":"15","author":"Zhou","year":"2019","journal-title":"Future Oncol."},{"issue":"10","key":"10.1016\/j.lungcan.2025.108856_b0150","doi-asserted-by":"crossref","first-page":"S836","DOI":"10.1016\/j.jtho.2019.08.1805","article-title":"P2.14-20 ATORG-003: Dacomitinib with or without dose titration as first-line therapy for metastatic EGFR mutant non-small cell lung cancer (NSCLC)","volume":"14","author":"Tan","year":"2019","journal-title":"J. Thorac. Oncol."},{"issue":"7","key":"10.1016\/j.lungcan.2025.108856_b0155","doi-asserted-by":"crossref","first-page":"783","DOI":"10.2217\/fon-2020-0888","article-title":"The patient's perspective on treatment with dacomitinib: patient-reported outcomes from the phase III trial ARCHER 1050","volume":"17","author":"Paty","year":"2021","journal-title":"Fut. Oncol."},{"key":"10.1016\/j.lungcan.2025.108856_b0160","doi-asserted-by":"crossref","first-page":"S1641","DOI":"10.1016\/j.annonc.2024.10.671","article-title":"638P Dacomitinib with or without dose titration in treatment na\u00efve advanced EGFR mutated NSCLC: primary analysis of the ATORG-003 phase II trial","volume":"35","author":"Tan","year":"2024","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2025.108856_b0165","doi-asserted-by":"crossref","DOI":"10.1136\/bmjresp-2022-001492","article-title":"Differential clinicopathological features, treatments and outcomes in patients with Exon 19 deletion and Exon 21 L858R EGFR mutation-positive adenocarcinoma non-small-cell lung cancer","volume":"10","author":"Batra","year":"2023","journal-title":"BMJ Open Respir. Res."},{"key":"10.1016\/j.lungcan.2025.108856_b0170","first-page":"119","article-title":"Efficacy according to blind independent central review: post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin\/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC","volume":"104","author":"Wu","year":"2017","journal-title":"Lung Can."},{"issue":"1","key":"10.1016\/j.lungcan.2025.108856_b0175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00228-015-1966-0","article-title":"Comparison of clinical outcomes of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations after tyrosine kinase inhibitors treatment: a meta-analysis","volume":"72","author":"Sheng","year":"2016","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"3","key":"10.1016\/j.lungcan.2025.108856_b0180","first-page":"e216","article-title":"Tyrosine kinase inhibitors for the treatment of EGFR mutation-positive non-small-cell lung cancer: a clash of the generations","volume":"21","author":"Shah","year":"2020","journal-title":"Clin. Lung Can."},{"issue":"2","key":"10.1016\/j.lungcan.2025.108856_b0185","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s40265-020-01441-6","article-title":"Updated overall survival in a randomized study comparing dacomitinib with gefitinib as first-line treatment in patients with advanced non-small-cell lung cancer and EGFR-activating mutations","volume":"81","author":"Mok","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.lungcan.2025.108856_b0190","first-page":"133","article-title":"EGFR mutation analysis for prospective patient selection in AURA3 phase III trial of osimertinib versus platinum-pemetrexed in patients with EGFR T790M-positive advanced non-small-cell lung cancer","volume":"126","author":"John","year":"2018","journal-title":"Lung Can."},{"issue":"1","key":"10.1016\/j.lungcan.2025.108856_b0195","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s12885-018-4075-5","article-title":"Frequency of the acquired resistant mutation T790M in non-small cell lung cancer patients with active exon 19Del and exon 21 L858R: a systematic review and meta-analysis","volume":"18","author":"Wang","year":"2018","journal-title":"BMC Can."},{"issue":"24","key":"10.1016\/j.lungcan.2025.108856_b0200","doi-asserted-by":"crossref","first-page":"3407","DOI":"10.1111\/1759-7714.14222","article-title":"Efficacy of dacomitinib in patients with EGFR-mutated NSCLC and brain metastases","volume":"12","author":"Zhang","year":"2021","journal-title":"Thorac Can."},{"issue":"21","key":"10.1016\/j.lungcan.2025.108856_b0205","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1056\/NEJMoa2306434","article-title":"Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC","volume":"389","author":"Planchard","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2025.108856_b0210","unstructured":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Non-Small Cell Lung Cancer V.8.2025. \u00a9 National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed October 15, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way."},{"issue":"1","key":"10.1016\/j.lungcan.2025.108856_b0215","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1186\/s12890-024-03336-8","article-title":"Optimal first-line treatment for EGFR-mutated NSCLC: a comparative analysis of osimertinib and second-generation EGFR-TKIs","volume":"24","author":"Chen","year":"2024","journal-title":"BMC Pulm. Med."},{"key":"10.1016\/j.lungcan.2025.108856_b0220","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.920479","article-title":"Cost-effectiveness of osimertinib versus standard EGFR-TKI as first-line treatment for EGFR-mutated advanced non-small-cell lung cancer in China","volume":"13","author":"Shu","year":"2022","journal-title":"Front. Pharmacol."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500225007482?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500225007482?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T17:22:45Z","timestamp":1769448165000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500225007482"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":44,"alternative-id":["S0169500225007482"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2025.108856","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world use of and clinical outcomes with dacomitinib as first-line therapy in Asian patients with EGFR mutation\u2013positive locally advanced or metastatic non-small cell lung cancer: Final analysis of the ARIA study","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2025.108856","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"108856"}}